Sab Biotherapeutics Stock Performance
| SABS Stock | USD 2.17 0.06 2.69% |
The firm owns a Beta (Systematic Risk) of -0.58, which indicates possible diversification benefits within a given portfolio. As returns on the market increase, returns on owning SAB Biotherapeutics are expected to decrease at a much lower rate. During the bear market, SAB Biotherapeutics is likely to outperform the market. At this point, SAB Biotherapeutics has a negative expected return of -0.29%. Please make sure to validate SAB Biotherapeutics' value at risk, and the relationship between the jensen alpha and skewness , to decide if SAB Biotherapeutics performance from the past will be repeated in the future.
Risk-Adjusted Performance
0 of 100
Weak | Strong |
Very Weak
Over the last 90 days SAB Biotherapeutics has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of weak performance in the last few months, the Stock's fundamental drivers remain comparatively stable which may send shares a bit higher in March 2025. The newest uproar may also be a sign of mid-term up-swing for the firm private investors. ...more
Actual Historical Performance (%)
One Day Return (2.69) | Five Day Return (39.89) | Year To Date Return (41.51) | Ten Year Return (97.86) | All Time Return (97.86) |
Last Split Factor 1:10 | Last Split Date 2024-01-05 |
1 | SAB BIO CEO to Participate in Fireside Chat at Guggenheim Securities Healthcare Innovation Conference - StockTitan | 10/31/2024 |
2 | Acquisition by Ellias Helen K. of 20000 shares of SAB Biotherapeutics at 3.88 subject to Rule 16b-3 | 11/01/2024 |
3 | SAB Biotherapeutics GAAP EPS of -1.12 | 11/07/2024 |
4 | Acquisition by Giberson Scott of 20000 shares of SAB Biotherapeutics at 2.9 subject to Rule 16b-3 | 11/08/2024 |
5 | SAB Biotherapeutics Buy Rating Reaffirmed at Chardan Capital | 11/11/2024 |
6 | Acquisition by Hamilton Christine E of 82987 shares of SAB Biotherapeutics subject to Rule 16b-3 | 11/25/2024 |
7 | Disposition of 9072 shares by Kropotova Alexandra of SAB Biotherapeutics subject to Rule 16b-3 | 12/18/2024 |
8 | Heres Why SAB Biotherapeutics, Inc. Is Among the Best Diabetes Stocks to Buy Under 10 | 01/06/2025 |
9 | Acquisition by Bausch Christoph Lawrence of 275000 shares of SAB Biotherapeutics at 0.54 subject to Rule 16b-3 | 01/30/2025 |
| Begin Period Cash Flow | 15 M |
SAB |
SAB Biotherapeutics Relative Risk vs. Return Landscape
If you would invest 404.00 in SAB Biotherapeutics on November 2, 2024 and sell it today you would lose (187.00) from holding SAB Biotherapeutics or give up 46.29% of portfolio value over 90 days. SAB Biotherapeutics is currently does not generate positive expected returns and assumes 11.6965% risk (volatility on return distribution) over the 90 days horizon. In different words, most equities are less risky than SAB, and most traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
SAB Biotherapeutics Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for SAB Biotherapeutics' investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as SAB Biotherapeutics, and traders can use it to determine the average amount a SAB Biotherapeutics' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = -0.0246
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns | SABS |
Estimated Market Risk
| 11.7 actual daily | 96 96% of assets are less volatile |
Expected Return
| -0.29 actual daily | 0 Most of other assets have higher returns |
Risk-Adjusted Return
| -0.02 actual daily | 0 Most of other assets perform better |
Based on monthly moving average SAB Biotherapeutics is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of SAB Biotherapeutics by adding SAB Biotherapeutics to a well-diversified portfolio.
SAB Biotherapeutics Fundamentals Growth
SAB Stock prices reflect investors' perceptions of the future prospects and financial health of SAB Biotherapeutics, and SAB Biotherapeutics fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on SAB Stock performance.
| Return On Equity | -1.75 | ||||
| Return On Asset | -0.79 | ||||
| Operating Margin | (34.23) % | ||||
| Current Valuation | (5.3 M) | ||||
| Shares Outstanding | 9.23 M | ||||
| Price To Book | 0.56 X | ||||
| Price To Sales | 13.24 X | ||||
| Revenue | 2.24 M | ||||
| Gross Profit | (25.38 M) | ||||
| EBITDA | (38.13 M) | ||||
| Net Income | (42.19 M) | ||||
| Cash And Equivalents | 16.62 M | ||||
| Cash Per Share | 0.39 X | ||||
| Total Debt | 5.91 M | ||||
| Debt To Equity | 0.16 % | ||||
| Current Ratio | 1.72 X | ||||
| Book Value Per Share | 4.00 X | ||||
| Cash Flow From Operations | (25.12 M) | ||||
| Earnings Per Share | (6.30) X | ||||
| Market Capitalization | 20.03 M | ||||
| Total Asset | 83.94 M | ||||
| Retained Earnings | (90.06 M) | ||||
| Working Capital | 48.09 M | ||||
About SAB Biotherapeutics Performance
Assessing SAB Biotherapeutics' fundamental ratios provides investors with valuable insights into SAB Biotherapeutics' financial health and overall profitability. This information is crucial for making informed investment decisions. A high ROA would indicate that the SAB Biotherapeutics is effectively leveraging its assets and equity to generate significant profits, making it an appealing investment. Conversely, low Return on Assets could signal underlying management issues in assets and equity, indicating a necessity for operational refinements. Please also refer to our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.58) | (0.55) | |
| Return On Capital Employed | (0.60) | (0.63) | |
| Return On Assets | (0.58) | (0.55) | |
| Return On Equity | (0.85) | (0.80) |
Things to note about SAB Biotherapeutics performance evaluation
Checking the ongoing alerts about SAB Biotherapeutics for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for SAB Biotherapeutics help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| SAB Biotherapeutics generated a negative expected return over the last 90 days | |
| SAB Biotherapeutics has high historical volatility and very poor performance | |
| SAB Biotherapeutics has high likelihood to experience some financial distress in the next 2 years | |
| The company reported the previous year's revenue of 2.24 M. Net Loss for the year was (42.19 M) with loss before overhead, payroll, taxes, and interest of (25.38 M). | |
| SAB Biotherapeutics currently holds about 16.62 M in cash with (25.12 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.39. | |
| SAB Biotherapeutics has a poor financial position based on the latest SEC disclosures | |
| Roughly 19.0% of the company outstanding shares are owned by corporate insiders | |
| Latest headline from MacroaxisInsider: Acquisition by Bausch Christoph Lawrence of 275000 shares of SAB Biotherapeutics at 0.54 subject to Rule 16b-3 |
- Analyzing SAB Biotherapeutics' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether SAB Biotherapeutics' stock is overvalued or undervalued compared to its peers.
- Examining SAB Biotherapeutics' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating SAB Biotherapeutics' management team can have a significant impact on its success or failure. Reviewing the track record and experience of SAB Biotherapeutics' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of SAB Biotherapeutics' stock. These opinions can provide insight into SAB Biotherapeutics' potential for growth and whether the stock is currently undervalued or overvalued.
Additional Tools for SAB Stock Analysis
When running SAB Biotherapeutics' price analysis, check to measure SAB Biotherapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy SAB Biotherapeutics is operating at the current time. Most of SAB Biotherapeutics' value examination focuses on studying past and present price action to predict the probability of SAB Biotherapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move SAB Biotherapeutics' price. Additionally, you may evaluate how the addition of SAB Biotherapeutics to your portfolios can decrease your overall portfolio volatility.